Chemo-Free combo shows promise for CLL patients

NCT ID NCT02666898

Completed Disease control Sponsor: French Innovative Leukemia Organisation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a chemotherapy-free combination of two drugs, obinutuzumab and ibrutinib, in 135 people with previously untreated chronic lymphocytic leukemia (CLL). The treatment was given for nine months, and then the next steps were decided based on how much leukemia remained in the bone marrow. The goal was to see if this approach could control the disease without traditional chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obinutuzumab (GA101) and ibrutinib (Imbruvica)
What this could lead to: If successful, this could point toward a chemotherapy-free treatment option for chronic lymphocytic leukemia that is tailored based on how well the disease responds.
What could go wrong: This is a phase 2 trial with only 135 participants, so results are not definitive. The treatment may not work for everyone, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL

Contacts and locations

Locations

Sponsor FILO

Tours, 37054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.